BCL-X

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

19 citing papers in PubMed.

1. Wired to Survive: How AML Cytogenetics Shape Apoptotic Dependence and Venetoclax Resistance.Genes · 2026
   Review
2. Functional profiling of ovarian cancer models reveals Bcl-xL/NOTCH targeting to overcome resistance.NPJ precision oncology · 2026
   Article
3. A novel CD7-directed antibody-drug conjugate targeting BCL-XL with potent anti-leukemic activity in T-cell acute lymphoblastic leukemia.Leukemia · 2026
   Article
4. Structure-Based Discovery of Potent BCL-XL Inhibitors through Rescaffolding.Journal of medicinal chemistry · 2026
   Article
5. Anti-apoptotic BCL-2 family proteins: from regulatory networks to therapeutic targeting.Oncogenesis · 2026
   Review
6. Bcl-xL blockade targets neutrophils and synergizes with chemotherapy in lung squamous cell carcinoma.EMBO molecular medicine · 2026
   Article
7. Differential mitochondrial priming by BCR::ABL1 in B-cell precursor acute lymphoblastic leukemia.Leukemia · 2026
   Article
8. BCL-2 and BCL-xL in Cancer: Regulation, Function, and Therapeutic Targeting.International journal of molecular sciences · 2026
   Review
9. Drivers of clinical resistance to venetoclax and hypomethylating agents in acute myeloid leukemia and strategies for improving efficacy.HemaSphere · 2026
   Article
10. Targeting BCL-XL-mediated apoptotic resistance in lung cancer:Frontiers in medicine · 2026
    Article
11. Developing therapeutic strategies to target MCL1 and BCLXL in lethal prostate cancer.iScience · 2025
    Article
12. The anticancer effect of the HDAC inhibitor belinostat is enhanced by inhibitors of Bcl-xMolecular oncology · 2025
    Article
13. BCL-xL dependency in chromophobe renal cell carcinoma.Cancer gene therapy · 2025
    Article
14. Molecular mechanisms underlying HRK interaction with BCL-XL and BCL-2 reveal specificity determinants for BH3 mimetics.iScience · 2025
    Article
15. Antibody-Drug Conjugates in Breast Cancer: Navigating Innovations, Overcoming Resistance, and Shaping Future Therapies.Biomedicines · 2025
    Review
16. The BCL-2 protein family: from discovery to drug development.Cell death and differentiation · 2025
    Review
17. De novo pyrimidine biosynthesis inhibition synergizes with BCL-XNature communications · 2025
    Article
18. Sensitivity to an inhibitor of translation elongation in solid and hematologic cancers.Scientific reports · 2025
    Article
19. Integrated molecular and functional characterization of the intrinsic apoptotic machinery identifies therapeutic vulnerabilities in glioma.Nature communications · 2024
    Article

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

Authors and funding

45 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract

Indexed as